Lead Program, THB001, a First-In-Class, Highly Selective, Oral KIT Inhibitor in Development for Multiple Allergic and Inflammatory Conditions, Is Currently in Phase 1 Clinical Development
$155 Million Raised to Date Expected to Fund Operations Beyond Completion of a Proof-of-Concept Study in Chronic Urticaria
